Eli Lilly and Company (NYSE:LLY – Get Free Report) and Biora Therapeutics (NASDAQ:BIOR – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, analyst recommendations, profitability, risk and dividends.
Risk and Volatility
Eli Lilly and Company has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Biora Therapeutics has a beta of 1.12, suggesting that its stock price is 12% more volatile than the S&P 500.
Profitability
This table compares Eli Lilly and Company and Biora Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eli Lilly and Company | 23.51% | 86.26% | 16.67% |
| Biora Therapeutics | N/A | N/A | -332.47% |
Valuation & Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Eli Lilly and Company | $45.04 billion | 18.07 | $5.24 billion | $11.71 | 73.22 |
| Biora Therapeutics | $892,000.00 | 0.62 | -$124.11 million | ($13.04) | -0.01 |
Eli Lilly and Company has higher revenue and earnings than Biora Therapeutics. Biora Therapeutics is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
82.5% of Eli Lilly and Company shares are held by institutional investors. Comparatively, 43.7% of Biora Therapeutics shares are held by institutional investors. 0.1% of Eli Lilly and Company shares are held by insiders. Comparatively, 51.1% of Biora Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of current ratings and recommmendations for Eli Lilly and Company and Biora Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eli Lilly and Company | 0 | 4 | 17 | 0 | 2.81 |
| Biora Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Eli Lilly and Company presently has a consensus target price of $997.50, indicating a potential upside of 16.34%. Biora Therapeutics has a consensus target price of $23.00, indicating a potential upside of 18,675.51%. Given Biora Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Biora Therapeutics is more favorable than Eli Lilly and Company.
Summary
Eli Lilly and Company beats Biora Therapeutics on 10 of the 14 factors compared between the two stocks.
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.
About Biora Therapeutics
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.
